We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Thermo Fisher Scientific’s TurboFlow Technology Reduces Matrix Effects in LC-MS/MS Analysis
Product News

Thermo Fisher Scientific’s TurboFlow Technology Reduces Matrix Effects in LC-MS/MS Analysis

Thermo Fisher Scientific’s TurboFlow Technology Reduces Matrix Effects in LC-MS/MS Analysis
Product News

Thermo Fisher Scientific’s TurboFlow Technology Reduces Matrix Effects in LC-MS/MS Analysis


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Thermo Fisher Scientific’s TurboFlow Technology Reduces Matrix Effects in LC-MS/MS Analysis"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Thermo Fisher Scientific Inc. has announced that the company’s TurboFlow™ technology can assist pharmaceutical researchers to comply with U.S. Food and Drug Administration (FDA) regulatory guidelines on matrix effects, particularly for LC-MS/MS analysis.

Thermo Scientific TurboFlow technology coupled with the Thermo Scientific TSQ Quantum™ triple quadrupole mass spectrometer and FAIMS (High-Field Asymmetric Ion Mobility Mass Spectrometry) technology provides an integrated LC-MS/MS solution.

When used with the TSQ Quantum, the system delivers quantitative results with the lowest ion suppression and chemical noise, resulting in sensitive bioanalytical methods, development of robust methods and reduction in analysis failures.

This solution can allow scientists to matrix effects during pre-clinical bioanalysis, making it easier to comply with the FDA/CDER Bioanalytical Method Validation Guidance that states: "In the case of LC-MS-MS-based procedures, appropriate steps should be taken to ensure the lack of matrix effects throughout the application of the method, especially if the nature of the matrix changes from the matrix used during method validation."

TurboFlow technology assists pharmaceutical researchers in reducing matrix effects by retaining small molecules, excluding proteins and larger materials. This enables users to directly inject biological samples into the LC-MS/MS system prior to analysis, an advantage in preclinical bioanalysis.

Advertisement